Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

Journal of Allergy and Clinical Immunology

Volumn 139, Issue 1, 2017, Pages 335-346.e3

  Pesce, Silvia ^a   Greppi, Marco ^a   Tabellini, Giovanna ^b   Rampinelli, Fabio ^c   Parolini, Silvia ^b   Olive, Daniel ^d   Moretta, Lorenzo ^e   Moretta, Alessandro ^a   Marcenaro, Emanuela ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SPEDALI CIVILI   (Italy)

^d AIX MARSEILLE UNIVERSITY   (France)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

CD57+ natural killer cells; cytomegalovirus; immune checkpoint; natural killer cell cytokine production; natural killer cell degranulation; natural killer cell proliferation; Natural killer cells; ovarian carcinoma; programmed death receptor; tumor escape

Indexed keywords

CD56 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; CYTOKINE; PDCD1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; FEMALE; IMMUNOLOGY; OVARY TUMOR; PHENOTYPE; PHYSIOLOGY;

CELL DEGRANULATION; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; KILLER CELLS, NATURAL; OVARIAN NEOPLASMS; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84977656292     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.04.025     Document Type: Article

References (69)

1. 1 Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8 (1996), 765–772.
2. 2 Vivier, E., Daeron, M., Immunoreceptor tyrosine-based inhibition motifs. Immunol Today 18 (1997), 286–291.
3. 3 Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
4. 4 Ghiotto, M., Gauthier, L., Serriari, N., Pastor, S., Truneh, A., Nunes, J.A., et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 22 (2010), 651–660.
5. 5 Zhang, L., Gajewski, T.F., Kline, J., PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114 (2009), 1545–1552.
6. 6 Watanabe, T., Bertoletti, A., Tanoto, T.A., PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 17 (2010), 453–458.
7. 7 Day, C.L., Kaufmann, D.E., Kiepiela, P., Brown, J.A., Moodley, E.S., Reddy, S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006), 350–354.
8. 8 Taborda, N.A., Hernandez, J.C., Lajoie, J., Juno, J.A., Kimani, J., Rugeles, M.T., et al. Short communication: low expression of activation and inhibitory molecules on NK cells and CD4(+) T cells is associated with viral control. AIDS Res Hum Retroviruses 31 (2015), 636–640.
9. 9 Zou, W., Chen, L., Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8 (2008), 467–477.
10. 10 Bour-Jordan, H., Esensten, J.H., Martinez-Llordella, M., Penaranda, C., Stumpf, M., Bluestone, J.A., Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241 (2011), 180–205.
11. 11 Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G.J., Minato, N., et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 84 (2002), 57–62.
12. 12 McDermott, D.F., Atkins, M.B., PD-1 as a potential target in cancer therapy. Cancer Med 2 (2013), 662–673.
13. 13 Macatangay, B.J., Rinaldo, C.R., PD-1 blockade: a promising immunotherapy for HIV?. Cellscience 5 (2009), 61–65.
14. 14 Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., Honjo, T., A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14 (2013), 1212–1218.
15. 15 Strome, S.E., Dong, H., Tamura, H., Voss, S.G., Flies, D.B., Tamada, K., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63 (2003), 6501–6505.
16. 16 Blank, C., Brown, I., Peterson, A.C., Spiotto, M., Iwai, Y., Honjo, T., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64 (2004), 1140–1145.
17. 17 Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (2005), 1089–1096.
18. 18 Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207 (2010), 2187–2194.
19. 19 Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
20. 20 Ribas, A., Tumor immunotherapy directed at PD-1. N Engl J Med 366 (2012), 2517–2519.
21. 21 Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M.C., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14 (1996), 619–648.
22. 22 Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19 (2001), 197–223.
23. 23 Lanier, L.L., NK cell receptors. Annu Rev Immunol 16 (1998), 359–393.
24. 24 Parham, P., MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5 (2005), 201–214.
25. 25 Sivori, S., Vitale, M., Bottino, C., Marcenaro, E., Sanseverino, L., Parolini, S., et al. CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. Eur J Immunol 26 (1996), 2487–2492.
26. 26 Braud, V.M., Allan, D.S., O'Callaghan, C.A., Soderstrom, K., D'Andrea, A., Ogg, G.S., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998), 795–799.
27. 27 Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M.C., Moretta, A., Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117 (2011), 764–771.
28. 28 Orange, J.S., Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol 6 (2006), 399–409.
29. 29 Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999), 727–729.
30. 30 Moretta, A., Sivori, S., Vitale, M., Pende, D., Morelli, L., Augugliaro, R., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182 (1995), 875–884.
31. 31 Marcenaro, E., Pesce, S., Sivori, S., Carlomagno, S., Moretta, L., Moretta, A., KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood 121 (2013), 3396–3401.
32. 32 Bottino, C., Sivori, S., Vitale, M., Cantoni, C., Falco, M., Pende, D., et al. A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. Eur J Immunol 26 (1996), 1816–1824.
33. 33 Pesce, S., Carlomagno, S., Moretta, A., Sivori, S., Marcenaro, E., Uptake of CCR7 by KIR2DS4(+) NK cells is induced upon recognition of certain HLA-C alleles. J Immunol Res, 2015, 2015, 754373.
34. 34 Caligiuri, M.A., Human natural killer cells. Blood 112 (2008), 461–469.
35. 35 Marcenaro, E., Carlomagno, S., Pesce, S., Della Chiesa, M., Parolini, S., Moretta, A., et al. NK cells and their receptors during viral infections. Immunotherapy 3 (2011), 1075–1086.
36. 36 Lee, J., Zhuang, Y., Wei, X., Shang, F., Wang, J., Zhang, Y., et al. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 46 (2009), 169–176.
37. 37 Benson, D.M. Jr., Bakan, C.E., Mishra, A., Hofmeister, C.C., Efebera, Y., Becknell, B., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116 (2010), 2286–2294.
38. 38 Wiesmayr, S., Webber, S.A., Macedo, C., Popescu, I., Smith, L., Luce, J., et al. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 42 (2012), 541–550.
39. 39 Marcenaro, E., Della Chiesa, M., Bellora, F., Parolini, S., Millo, R., Moretta, L., et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 174 (2005), 3992–3998.
40. 40 Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology, 4, 2015, e1001224.
41. 41 Mavilio, D., Lombardo, G., Benjamin, J., Kim, D., Follman, D., Marcenaro, E., et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 102 (2005), 2886–2891.
42. 42 Della Chiesa, M., Falco, M., Podesta, M., Locatelli, F., Moretta, L., Frassoni, F., et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood 119 (2012), 399–410.
43. 43 Guma, M., Budt, M., Saez, A., Brckalo, T., Hengel, H., Angulo, A., et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107 (2006), 3624–3631.
44. 44 Falco, M., Biassoni, R., Bottino, C., Vitale, M., Sivori, S., Augugliaro, R., et al. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Exp Med 190 (1999), 793–802.
45. 45 Brunetta, E., Fogli, M., Varchetta, S., Bozzo, L., Hudspeth, K.L., Marcenaro, E., et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 114 (2009), 3822–3830.
46. 46 Brunetta, E., Fogli, M., Varchetta, S., Bozzo, L., Hudspeth, K.L., Marcenaro, E., et al. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 24 (2010), 27–34.
47. 47 Muntasell, A., Lopez-Montanes, M., Vera, A., Heredia, G., Romo, N., Penafiel, J., et al. NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol 43 (2013), 3268–3278.
48. 48 Luetke-Eversloh, M., Hammer, Q., Durek, P., Nordstrom, K., Gasparoni, G., Pink, M., et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog, 10, 2014, e1004441.
49. 49 Guma, M., Angulo, A., Vilches, C., Gomez-Lozano, N., Malats, N., Lopez-Botet, M., Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104 (2004), 3664–3671.
50. 50 Bjorkstrom, N.K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivarsson, M.A., et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116 (2010), 3853–3864.
51. 51 Lopez-Verges, S., Milush, J.M., Pandey, S., York, V.A., Arakawa-Hoyt, J., Pircher, H., et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116 (2010), 3865–3874.
52. 52 Moretta, L., Dissecting CD56dim human NK cells. Blood 116 (2010), 3689–3691.
53. 53 Brandt, C.S., Baratin, M., Yi, E.C., Kennedy, J., Gao, Z., Fox, B., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206 (2009), 1495–1503.
54. 54 Boussiotis, V.A., Chatterjee, P., Li, L., Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 20 (2014), 265–271.
55. 55 Ciccone, E., Pende, D., Nanni, L., Di Donato, C., Viale, O., Beretta, A., et al. General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect. Int Immunol 7 (1995), 393–400.
56. 56 Okazaki, T., Iwai, Y., Honjo, T., New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14 (2002), 779–782.
57. 57 Odorizzi, P.M., Pauken, K.E., Paley, M.A., Sharpe, A., Wherry, E.J., Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 212 (2015), 1125–1137.
58. 58 Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., Yao, Y., Zang, X., Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21 (2015), 24–33.
59. 59 MacFarlane, A.W., Jillab, M., Plimack, E.R., Hudes, G.R., Uzzo, R.G., Litwin, S., et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2 (2014), 320–331.
60. 60 Alvarez, I.B., Pasquinelli, V., Jurado, J.O., Abbate, E., Musella, R.M., de la Barrera, S.S., et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis 202 (2010), 524–532.
61. 61 Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
62. 62 Wenjin, Z., Chuanhui, P., Yunle, W., Lateef, S.A., Shusen, Z., Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B. BMC Gastroenterol, 12, 2012, 109.
63. 63 Norris, S., Coleman, A., Kuri-Cervantes, L., Bower, M., Nelson, M., Goodier, M.R., PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol 25 (2012), 329–332.
64. 64 Min-Oo, G., Lanier, L.L., Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection. J Exp Med 211 (2014), 2669–2680.
65. 65 Schlums, H., Cichocki, F., Tesi, B., Theorell, J., Beziat, V., Holmes, T.D., et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42 (2015), 443–456.
66. 66 Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33 (2015), 4015–4022.
67. Ghiotto, M., Gauthier, L., Serriari, N., et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 22 (2010), 651–660.
68. Ciccone, E., Pende, D., Nanni, L., et al. General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect. Int Immunol 7 (1995), 393–400.
69. Pesce, S., Tabellini, G., Cantoni, C., et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology, 4, 2015, e1001224.